Evidence map›Paper›PMID 27020682›Full record

ArticleCancer immunology, immunotherapy : CII2016

Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma.

Fergus Noble, Toby Mellows, Leo H McCormick Matthews, Adrian C Bateman, Scott Harris, Timothy J Underwood, James P Byrne, Ian S Bailey, Donna M Sharland, Jamie J Kelly and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 2 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 2 syntheses or guidelines pooled it, 110 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Fergus NobleCancer Sciences Unit, Faculty of Medicine, University of Southampton, Somers Cancer Research Building (MP824), Southampton General Hospital, Tremona Road, Southampton, UK. f.noble@soton.ac.uk.
Toby MellowsCancer Sciences Unit, Faculty of Medicine, University of Southampton, Somers Cancer Research Building (MP824), Southampton General Hospital, Tremona Road, Southampton, UK.
Leo H McCormick MatthewsCancer Sciences Unit, Faculty of Medicine, University of Southampton, Somers Cancer Research Building (MP824), Southampton General Hospital, Tremona Road, Southampton, UK.
Adrian C BatemanDepartment of Cellular Pathology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Scott HarrisPublic Health Sciences and Medical Statistics, Faculty of Medicine, University of Southampton, Southampton, UK.
Timothy J UnderwoodCancer Sciences Unit, Faculty of Medicine, University of Southampton, Somers Cancer Research Building (MP824), Southampton General Hospital, Tremona Road, Southampton, UK.
James P ByrneDepartment of Surgery, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Ian S BaileyDepartment of Surgery, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Donna M SharlandDepartment of Surgery, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Jamie J KellyDepartment of Surgery, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
John N PrimroseCancer Sciences Unit, Faculty of Medicine, University of Southampton, Somers Cancer Research Building (MP824), Southampton General Hospital, Tremona Road, Southampton, UK.
Surinder S SahotaCancer Sciences Unit, Faculty of Medicine, University of Southampton, Somers Cancer Research Building (MP824), Southampton General Hospital, Tremona Road, Southampton, UK.
Andrew R BatemanCancer Sciences Unit, Faculty of Medicine, University of Southampton, Somers Cancer Research Building (MP824), Southampton General Hospital, Tremona Road, Southampton, UK.
Gareth J ThomasCancer Sciences Unit, Faculty of Medicine, University of Southampton, Somers Cancer Research Building (MP824), Southampton General Hospital, Tremona Road, Southampton, UK.
Christian H OttensmeierCancer Sciences Unit, Faculty of Medicine, University of Southampton, Somers Cancer Research Building (MP824), Southampton General Hospital, Tremona Road, Southampton, UK.
University of Southampton · GBUniversity Hospital Southampton NHS Foundation Trust · GBSouthampton General Hospital · GB

Funding

Cancer Research UK 15951Cancer Research UK 18158Cancer Research UK 18161Medical Research Council G1002565
6 · The paper itself

Abstract

backgroundOesophageal adenocarcinoma (OAC) is increasingly common in the west, and survival remains poor at 10-15 % at 5 years. Immune responses are increasingly implicated as a determining factor of tumour progression. The ability of lymphocytes to recognise tumour antigens provides a mechanism for a host immune attack against cancer providing a potential treatment strategy. MATERIALS AND

methodsTumour infiltrating lymphocytes (TILs: CD3+, CD4+, CD8+ and FOXp3+) were assessed by immunohistochemistry using tissue microarrays in a contemporary and homogeneous cohort of OAC patients (n = 128) undergoing curative treatment.

resultsMultivariate analysis identified three independent prognostic factors for improved cancer-specific survival (CSS): increased CD8+ TILs (p = 0.003), completeness of resection (p < 0.0001) and lower pathological N stage (p < 0.0001). Independent prognostic factors for favourable disease-free survival included surgery-only treatment (p = 0.015), completeness of resection (p = 0.001), increased CD8+ TILs (p < 0.0001) and reduced pathological N stage (p < 0.0001). Higher levels of TILs in the pathological specimen were associated with significant pathological response to neoadjuvant chemotherapy (NAC). On multivariate analysis increased levels of CD4+ (p = 0.017) and CD8+ TILs (p = 0.005) were associated with significant local tumour regression and lymph node downstaging, respectively. DISCUSSION: Our results establish an association of TILs and survival in OAC, as seen in other solid tumours, and identify particular TIL subsets that are present at higher levels in patients who responded to NAC compared to non-responders. These findings highlight potential therapeutic strategies in EAC based on utilising the host immunological response and highlight the immune responses biomarker potential.

Indexed as

AdenocarcinomaAgedAged, 80 and overBiomarkersCombined Modality TherapyDisease ProgressionEsophageal NeoplasmsFemaleFollow-Up StudiesHumansImmunohistochemistryInflammation MediatorsKaplan-Meier EstimateLymphocytes, Tumor-InfiltratingLymphocyte SubsetsMaleBiomarkersInflammation MediatorsCytotoxic T lymphocyteImmune responseImmunotherapyOesophageal adenocarcinomaRegulatory T cellsTumour regression

Identifiers

PMID27020682
PMCPMC4880639
OpenAlexW2334750499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.